title: Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.
abstract: Previous studies have demonstrated that the -141C Ins/Del and TaqI A polymorphisms in the DRD2 gene affect the density of the dopamine D2 receptor. The present study examines the correlation between these two polymorphisms and the therapeutic response to chlorpromazine, a typical antipsychotic drug, in 135 inpatients with schizophrenia. Clinical symptoms were evaluated using the Brief Psychiatry Rating Scale (BPRS) before and after 8 weeks of treatment with 300-600 mg/day of chlorpromazine. Our results show that genotyping -141C Ins/Del may help to predict the efficacy of chlorpromazine treatment (P=0.01) due to the fact that patients with no Del allele showed greater improvement than those with Del allele on the overall BPRS (P=0.03), and that, therefore, the potential for therapy in patients with schizophrenia is related to the -141C Ins/Del polymorphism in the DRD2 gene. However, no such relationship was found for the TaqI A polymorphism.
authors.affiliation: Bio-X Life Science Research Center, Shanghai Jiao Tong University, 1954 Huashan Road, Shanghai 200030, PR China.
authors.forename: Shengnan
authors.initials: S
authors.lastname: Wu
authors.forename: Qinghe
authors.initials: Q
authors.lastname: Xing
authors.forename: Rui
authors.initials: R
authors.lastname: Gao
authors.forename: Xingwang
authors.initials: X
authors.lastname: Li
authors.forename: Niufan
authors.initials: N
authors.lastname: Gu
authors.forename: Guoyin
authors.initials: G
authors.lastname: Feng
authors.forename: Lin
authors.initials: L
authors.lastname: He
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002681:China / Q000453:epidemiology; D002746:Chlorpromazine / Q000627:therapeutic use*; D005260:Female; D017353:Gene Deletion; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D011110:Polymorphism, Genetic; D011569:Psychiatric Status Rating Scales; D012333:RNA, Messenger / Q000096:biosynthesis; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D050638:Receptors, Dopamine D4; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics*; D019914:Taq Polymerase
chemical_list: D014150:Antipsychotic Agents; C493599:DRD4 protein, human; D012333:RNA, Messenger; D017448:Receptors, Dopamine D2; D050638:Receptors, Dopamine D4; D019914:Taq Polymerase; D002746:Chlorpromazine